Core Viewpoint - The company, Renfu Pharmaceutical, announced that its subsidiary, Wuhan Renfu Likang Pharmaceutical Co., Ltd., received a tentative approval number from the U.S. Food and Drug Administration (FDA) for Oxcarbazepine extended-release tablets, which are intended for the treatment of partial seizures in patients aged 6 and older [1]. Company Summary - Renfu Pharmaceutical holds a 75.33% stake in Wuhan Renfu Likang, with plans to acquire 100% equity based on a future repurchase agreement [1]. - The approved product, Oxcarbazepine extended-release tablets, targets a specific patient demographic, indicating a focused approach in the company's product development strategy [1].

证券代码：600079 证券简称：人福医药 编号：临 2025-113 人福医药集团股份公司（以下简称"公司"）控股子公司武汉人福利康药业有限公 司（以下简称"人福利康"，公司及全资子公司持有其75.33%的股权，根据增资协议的 远期回购约定，公司持有其100%权益）收到美国食品药品监督管理局（FDA）关于奥 卡西平缓释片的暂定批准文号，现将主要情况公告如下： 药品名称：Oxcarbazepine Extended-Release Tablets （奥卡西平缓释片） 申请事项：ANDA（美国仿制药申请）。由于原研药"OXTELLAR XR"仍处在专 利保护期，此ANDA获得美国FDA暂定批准。 ANDA批件号：219673 剂型：片剂 规格：150 mg、600 mg 药品类型：处方药 人福医药集团股份公司 关于奥卡西平缓释片获得美国 FDA 暂定批准文号的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法 律责任。 奥卡西平缓释片用于治疗6岁及以上癫痫患者的部分性发作。人福利康于2024年向 FDA递交该ANDA申请并成功受理，截 ...

Core Viewpoint - The company, Renfu Pharmaceutical, announced that its subsidiary, Wuhan Renfu Likang Pharmaceutical Co., Ltd., received a tentative approval number from the U.S. Food and Drug Administration (FDA) for Oxcarbazepine extended-release tablets, which are used to treat partial seizures in patients aged 6 years and older [1]. Group 1 - The FDA's tentative approval indicates a significant milestone for the company in expanding its product offerings in the U.S. market [1]. - Oxcarbazepine extended-release tablets are specifically indicated for the treatment of partial seizures, highlighting the company's focus on addressing neurological conditions [1].

Core Viewpoint - The announcement indicates that Renfu Pharmaceutical's subsidiary, Renfu Likang Pharmaceutical Co., Ltd., has received a tentative approval number from the FDA for Oxcarbazepine extended-release tablets, which are intended for the treatment of partial seizures in patients aged 6 and above [1] Group 1: Product Development - Renfu Likang has invested approximately 15 million RMB in the research and development of Oxcarbazepine extended-release tablets [1] - The total sales revenue for Oxcarbazepine extended-release tablets in the U.S. market is projected to be around 216 million USD in 2024 [1] Group 2: Patent and Market Entry - Supernus currently holds the patent for Oxcarbazepine extended-release tablets, which is set to expire on April 13, 2027 [1] - Renfu Likang can only launch the product in the U.S. market after the patent expiration and the final approval from the FDA [1]

Group 1 - The company, Renfu Pharmaceutical, announced that its subsidiary, Wuhan Renfulikang Pharmaceutical Co., Ltd., received a tentative approval number from the U.S. Food and Drug Administration (FDA) for Oxcarbazepine extended-release tablets [1] - The Oxcarbazepine extended-release tablets are indicated for the treatment of partial seizures in patients aged 6 years and older [1]

Group 1 - The core point of the article is that Renfu Pharmaceutical has received a tentative approval number from the US FDA for its drug Oxycarbazepine extended-release tablets, which are intended for the treatment of partial seizures in patients aged 6 and older [2] - The company has invested approximately 15 million RMB in the research and development of this drug [2] - Several manufacturers, in addition to the original manufacturer Supernus, have received either formal or tentative approval numbers for this product [2] Group 2 - The product can only be marketed in the US after the original drug's patent expires and the FDA grants final approval [2] - The company has issued a reminder to investors to be aware of investment risks associated with this development [2]

Group 1 - The first sublingual nerve stimulation implant surgery in China was completed, marking a significant advancement in the treatment of obstructive sleep apnea (OSA) [1] - The surgery was performed by a multidisciplinary team, resulting in a notable reduction in apnea episodes and improvement in sleep quality for the patient [1] - This procedure represents a new direction in clinical applications of neural interfaces, potentially driving the development of sleep medicine, wearable monitoring, and rehabilitation management industries [1] Group 2 - Haizheng Pharmaceutical signed an exclusive licensing and strategic cooperation agreement with Aixin Dawei to introduce the first-in-class small molecule prodrug AST-3424 in China [2] - The collaboration aims to enhance Haizheng's innovative drug portfolio and leverage Aixin Dawei's promising research pipeline, potentially accelerating the introduction of new cancer treatment options [2] Group 3 - Renfu Pharmaceutical's subsidiary received a drug registration certificate for Levonorgestrel tablets from the National Medical Products Administration [3] - The approval is significant as it addresses the stable demand for emergency contraceptives, enhancing Renfu's product line and competitive position in the women's health medication market [3] Group 4 - Dairui Biotechnology's clinical trial application for RN3161, a GalNAc-siRNA targeting INHBE, has been accepted in Australia [4] - RN3161 aims to provide a long-term weight loss therapy for overweight and obese individuals, addressing urgent treatment needs and filling a market gap if successful [4] Group 5 - New Element Pharmaceuticals submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities as the sole sponsor [5] - The company focuses on developing therapies for metabolic, inflammatory, and cardiovascular diseases, with a promising product pipeline [5] - The listing is expected to accelerate research and market expansion, although the industry is highly competitive and poses significant development risks [5]

Group 1 - The first sublingual nerve stimulation implant surgery in China was successfully completed, marking a significant advancement in the treatment of obstructive sleep apnea (OSA) [1] - The surgery was performed by a multidisciplinary team and resulted in a notable reduction in breathing pauses and improvement in sleep quality for the patient [1] - This procedure represents a new direction in clinical applications of neural interfaces, potentially driving the development of sleep medicine, wearable monitoring, and rehabilitation management industries [1] Group 2 - Haizheng Pharmaceutical signed an exclusive licensing and strategic cooperation agreement with Aixin Dawei to introduce the first-in-class small molecule prodrug AST-3424 in China [2] - The collaboration aims to enhance Haizheng's innovative drug portfolio and leverage Aixin Dawei's promising research pipeline, potentially accelerating the introduction of new cancer treatment options [2] Group 3 - Renfu Pharmaceutical's subsidiary received a drug registration certificate for "Levonorgestrel Tablets" from the National Medical Products Administration [3] - The approval is significant as it addresses the stable demand for emergency contraceptives, enhancing Renfu's product line and competitive position in the women's health medication market [3] Group 4 - Dairui Biotechnology's clinical trial application for RN3161, a GalNAc-siRNA targeting INHBE, has been accepted in Australia [4] - RN3161 aims to provide a long-term weight loss solution for overweight and obese individuals, addressing urgent treatment needs and filling a market gap left by existing GLP-1 drugs [4] Group 5 - New Element Pharmaceuticals submitted its listing application to the Hong Kong Stock Exchange, with CITIC Securities as the sole sponsor [5] - The company focuses on developing therapies for metabolic, inflammatory, and cardiovascular diseases, with a promising product pipeline that includes ABP-671 and ABP-745 [5] - The listing is expected to accelerate research and market expansion, although the industry is highly competitive and poses significant development risks [5]

Core Viewpoint - The approval of Fluorobiphenyl Ester Injection and Levonorgestrel Tablets marks significant advancements for the company in expanding its product pipeline and enhancing its market presence in the pharmaceutical industry [1][4]. Group 1: Fluorobiphenyl Ester Injection - The company’s subsidiary, Yichang Renfu Pharmaceutical, received the drug registration certificate for Fluorobiphenyl Ester Injection from the National Medical Products Administration [1]. - The injection is a non-steroidal analgesic suitable for postoperative and cancer pain management, with a cumulative R&D investment of approximately RMB 35 million [2]. - The projected national sales for Fluorobiphenyl Ester Injection in 2024 are around RMB 980 million, with major competitors including Beijing Tide Pharmaceutical and Wuhan Yanda Medical Nutrition Science [2]. - The approval allows the company to sell the product in the domestic market, which is expected to positively impact its business [2]. Group 2: Levonorgestrel Tablets - The company’s subsidiary, Wuhan Jiulong Renfu Pharmaceutical, received the drug registration certificate for Levonorgestrel Tablets from the National Medical Products Administration [4]. - Levonorgestrel Tablets are indicated for emergency contraception, with a cumulative R&D investment of approximately RMB 13.5 million [5]. - The projected national sales for Levonorgestrel Tablets in 2024 are around RMB 1.14 billion, with key competitors including China Resources Zizhu Pharmaceutical and Gedeon Richter Plc [5]. - The approval signifies the company’s eligibility to market the product domestically, which is anticipated to further enrich its product line and positively influence its financial performance [5].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 34.83 CNY [6][13]. Core Insights - The company is a leading player in the domestic anesthetic and psychotropic drug market, operating in a high-barrier industry where the impact of centralized procurement is stabilizing. There is a focus on the gradual realization of innovative results [2][3]. - The company has shown steady growth in its core business segments, with anesthetic revenue reaching 1.634 billion CNY in the first half of 2025, a year-on-year increase of 7.32%, and a gross margin of 90.80%, which is an increase of 3.64 percentage points [13]. - The company is actively developing innovative drugs in the central nervous system field, with multiple pipelines that have potential for future growth, including drugs for schizophrenia, depression, Parkinson's disease, and Alzheimer's disease [13]. Financial Summary - Total revenue is projected to grow from 5,042 million CNY in 2023 to 8,143 million CNY in 2027, reflecting a compound annual growth rate (CAGR) of approximately 12.2% [4][14]. - Net profit attributable to the parent company is expected to increase from 1,037 million CNY in 2023 to 1,776 million CNY in 2027, with a CAGR of about 15.0% [4][14]. - Earnings per share (EPS) is forecasted to rise from 1.02 CNY in 2023 to 1.75 CNY in 2027 [4][14]. Market Data - The company's market capitalization is approximately 28.95 billion CNY, with a current stock price of 28.50 CNY [7][13]. - The stock has a price-to-earnings (P/E) ratio of 27.92 based on the current price and diluted share capital [4][14]. Competitive Position - The company operates in a relatively stable competitive landscape, with strict government regulations governing the production and transportation of anesthetic and psychotropic drugs, which helps maintain its market position [13].